Compare BTOC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | TOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 14.7M |
| IPO Year | 2023 | 2012 |
| Metric | BTOC | TOVX |
|---|---|---|
| Price | $0.28 | $0.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.00 | $1.00 |
| AVG Volume (30 Days) | 196.1K | ★ 22.2M |
| Earning Date | 05-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,408,258.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $0.23 | $0.16 |
| 52 Week High | $1.78 | $0.86 |
| Indicator | BTOC | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 40.87 |
| Support Level | $0.27 | $0.17 |
| Resistance Level | $0.34 | $0.31 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.44 | 5.67 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.